Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 248.47Cr 218.8Cr 207.31Cr 187.15Cr 352.74Cr 24TCr 357.3Cr 2.48TCr 954.49Cr 12TCr 933Cr 912.65Cr 39TCr | P/E 2026 * |
-7.54x | P/E 2027 * | -7.41x |
|---|---|---|---|---|---|
| Enterprise Value | 182.24Cr 160.48Cr 152.05Cr 137.27Cr 258.71Cr 17TCr 262.05Cr 1.82TCr 700.06Cr 8.93TCr 684.29Cr 669.37Cr 29TCr | EV / Sales 2026 * |
985x | EV / Sales 2027 * | 186x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 248.47Cr | |
| +4.16% | -0.30% | +58.96% | +94.17% | 7.15TCr | |
| -0.19% | -1.01% | +38.55% | +83.85% | 6.01TCr | |
| -1.51% | +2.20% | +10.66% | +35.15% | 4.89TCr | |
| -0.05% | +0.37% | +41.54% | +38.67% | 4.43TCr | |
| +0.38% | +7.61% | +339.53% | +684.33% | 4.38TCr | |
| +0.18% | +0.26% | +7.41% | +105.01% | 4.15TCr | |
| -0.67% | -0.45% | +4.47% | +46.37% | 3.01TCr | |
| +4.77% | +6.46% | +41.54% | +22.78% | 2.8TCr | |
| -1.29% | -3.55% | -20.74% | +349.90% | 2.53TCr | |
| Average | +1.70% | +0.48% | +57.99% | +162.25% | 4.37TCr | |
| Weighted average by Cap. | +0.92% | +0.63% | +63.17% | +153.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.5L 16.29L 15.43L 13.93L 26.26L 18Cr 26.6L 1.85Cr 71.06L 9.07Cr 69.46L 67.95L 29Cr | 99.54L 87.66L 83.05L 74.98L 1.41Cr 95Cr 1.43Cr 9.94Cr 3.82Cr 49Cr 3.74Cr 3.66Cr 156.44Cr |
| Net income | -32Cr -28Cr -27Cr -24Cr -45Cr -3.06TCr -46Cr -318.61Cr -122.61Cr -1.56TCr -119.85Cr -117.24Cr -5.02TCr | -36Cr -32Cr -30Cr -27Cr -51Cr -3.46TCr -52Cr -360.3Cr -138.66Cr -1.77TCr -135.53Cr -132.58Cr -5.67TCr |
| Net Debt | -66Cr -58Cr -55Cr -50Cr -94Cr -6.35TCr -95Cr -661.15Cr -254.43Cr -3.25TCr -248.7Cr -243.28Cr -10TCr | -63Cr -56Cr -53Cr -48Cr -90Cr -6.07TCr -91Cr -632.34Cr -243.34Cr -3.11TCr -237.86Cr -232.68Cr -9.95TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
